Algert Global’s TScan Therapeutics TCRX Stock Holding History

Algert Global’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-28,030	Closed	-$51K	–	1318
2025 Q3	$51K	Hold	28,030	–	–	﹤0.01%	1110
2025 Q2	$41K	Buy	+28,030	New	+$40.5K	﹤0.01%	1164

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Algert Global's TCRX Position: Q4 2025 in Review

Algert Global sold out of TScan Therapeutics (TCRX) in Q4 2025, closing a stake of 28,030 shares — an estimated $51K sold.

Algert Global first reported a position in TCRX in Q2 2025 and held it in 2 quarters. The position peaked at $51K in Q3 2025. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

Algert Global reported no remaining TScan Therapeutics position as of Q4 2025 after selling out during the quarter.
Algert Global sold 28,030 TScan Therapeutics shares in Q4 2025, an estimated $51K.
Algert Global first reported a position in TScan Therapeutics in Q2 2025 and held it in 2 quarters.
Algert Global's TScan Therapeutics position peaked at $51K in Q3 2025.
61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on Algert Global's 13F filing for Q4 2025, filed 17 Feb 2026.